Botulinum neurotoxin serotype F: Identification of substrate recognition requirements and development of inhibitors with low nanomolar affinity

Biochemistry

Volumn 44, Issue 10, 2005, Pages 4067-4073

  Schmidt, James J ^a   Stafford, Robert G ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINES; CHEMICAL BONDS; CHEMICAL REACTIONS; MEDICINE; MOLECULES; POLYPEPTIDES; PROTEINS; SUBSTRATES; ZINC;

BOTULINUM NEUROTOXINS (BONT); HUMAN MEDICINE; NEUROTOXINS; VESICLE-ASSOCIATED MEMBRANE PROTEINS (VAMP);

TOXIC MATERIALS;

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; BOTULINUM TOXIN F; CYSTEINE; GLUTAMINE; LIGAND; METALLOPROTEINASE; SYNAPTOBREVIN; UNCLASSIFIED DRUG; ZINC;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN MOTIF;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTITOXINS; BOTULINUM TOXINS; CATALYSIS; CYSTEINE; HUMANS; HYDROLYSIS; KINETICS; MEMBRANE PROTEINS; METALLOPROTEASES; MOLECULAR SEQUENCE DATA; NANOTECHNOLOGY; PEPTIDE FRAGMENTS; PROTEASE INHIBITORS; PROTEIN BINDING; R-SNARE PROTEINS; SEROTYPING; SUBSTRATE SPECIFICITY; SULFHYDRYL COMPOUNDS;

EID: 14844365792     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi0477642     Document Type: Article

References (55)

1. Schiavo, G., Matteoli, M., and Montecucco, C. (2000) Neurotoxins affecting neuroexocytosis, Physiol. Rev. 80, 717-766.
2. Harvey, S. M., Sturgeon, J., and Dassey, D. E. (2002) Botulism due to Clostridium baratii type F toxin. J. Clin. Microbiol. 40, 2260-2262.
3. Fenicia, L., Franciosa, G., Pourshaban, M., and Aureli, P. (1999) Intestinal toxemia botulism in two young people, caused by Clostridium butyricum type E, Clin. Infect. Dis. 29, 1381-1387.
4. Singh, B. R. (2000) Intimate details of the most poisonous poison, Nat. Struct. Biol. 7, 617-619.
5. Kalluri, P., Crowe, C., Reller, M., Gaul, L., Hayslett, J., Barth, S., Eliasberg, S., Ferreira, J., Holt, K., Bengston, S., Hendricks, K., and Sobel, J. (2003) An outbreak of foodborne botulism associated with food sold at a salvage store in Texas, Clin. Infect. Dis. 37, 1490-1495.
6. Werner, S. B., Passaro, D., McGee, J., Schechter, R., and Vugia, D. J. (2000) Wound botulism in California, 1951-1998: Recent epidemic in heroin users, Clin. Infect. Dis. 31, 1018-1024.
7. Barash, J. R., and Arnon, S. S. (2004) Dual toxin-producing strain of Clostridium botulium type Bf isolated from a California patient with infant botulism, J. Clin. Microbiol. 42, 1713-1715.
8. Nieman, H., Blasi, J., and Jahn, R. (1994) Clostridial neurotoxins: New tools for dissecting exocytosis, Trends Cell Biol. 5, 179-185.
9. Schiavo, G., Rossetto, O., and Montecucco, C. (1994) Clostridial neurotoxins as tools to investigate the molecular events of neurotransmitter release, Semin. Cell Biol. 4, 221-229.
10. Pellizzari, R., Rossetto, O., Schiavo, G., and Montecucco, C. (1999) Tetanus and botulinum neurotoxins: Mechanism of action and therapeutic uses, Philos. Trans. R. Soc. London 354, 259-268.
11. Rossetto, O., Seveso, M., Caccin, P., Schiavo, G., and Montecucco, C. (2001) Tetanus and botulinum neurotoxins: Turning bad guys into good by research, Toxicon 39, 27-41.
12. Turton, K., Chaddock, J. A., and Acharya, K. R. (2002) Botulinum and tetanus neurotoxins: Structure, function, and therapeutic utility, Trends Biochem. Sci. 27, 552-558.
13. Cherington, M. (2004) Botulism: Update and review, Semin. Neurol. 24, 155-163.
14. Arnon, S. S., Schechter, R., Inglesby, T. V., Henderson, D. A., Bartlett, J. G., Ascher, M. S., Eitzen, E., Fine, A. D., Hauer, J., Layton, M., Lillibridge, S., Osterholm. M. T., O'Toole, T., Parker, G., Russel, P. K., Swerdlow, D. L., and Tonat, K. (2001) Botulinum toxin as a biological weapon, J. Am. Med. Assoc. 285, 1059-1070.
15. Simpson, L. L. (2004) Identification of the major steps in botulinum toxin action, Annu. Rev. Pharmacol. Toxicol. 44, 167-193.
16. Koriazova, L. K., and Montal, M. (2003) Translocation of botulinum neurotoxin light chain protease through the heavy chain channel, Nat. Struct. Biol. 10, 13-18.
17. Maksymowych, A. B., and Simpson, L. L. (1998) Binding and transcytosis of botulinum neurotoxin by polarized human colon carcinoma cells, J. Biol. Chem. 273, 21950-21957.
18. Byrne, M. P., and Smith, L. A. (2000) Development of vaccines for prevention of botulism, Biochimie 82, 955-966.
19. Shi, Y. L., and Wang, Z. F. (2004) Cure of experimental botulism and antibotulismic effect of toosendanin. Acta Pharmacol. Sin. 25, 839-848.
20. Keller, J. E., Cai, F., and Neale, E. A. (2004) Uptake of botulinum neurotoxin into cultured neurons, Biochemistry 43, 526-532.
21. Foran, P., Shone, C. C., and Dolly, J. O. (1994) Differences in the protease activities of tetanus and botulinum B toxins revealed by the cleavage of vesicle-associated membrane protein and various sized fragments, Biochemistry 33, 15365-15374.
22. Deshpande, S. S., Sheridan, R. E., and Adler, M. (1995) A study of zinc-dependent metallopeptidase inhibitors as pharmacologic antagonists in botulinum neurotoxin poisoning, Toxicon 33, 551 - 557.
23. Adler, M., Nicholson, J. D., Starks, D. F., Kane, C. T., Cornille, F., and Hackley, B. E. (1999) Evaluation of phosphoramidon and three synthetic phosphonates for inhibition of botulinum neurotoxin B catalytic activity, J. Appl. Toxicol. 19, S5-S11.
24. Adler, M., Dinterman, R. E., and Wannemacher, R. W. (1997) Protection by the heavy metal chelator N,N,N′,N′-tetrakis(2-pyridylmethyl) ethylenediamine (TPEN) against the lethal action of botulinum neurotoxin A and B, Toxicon 35, 1089-1100.
25. Humeau, Y., Doussau, F., Grant, N., and Poulain, B. (2000) How botulinum and tetanus neurotoxins block neurotransmitter release, Biochimie 82, 427-446.
26. Rossetto, O., Schiavo, G., Montecucco, C., Poulaun, B., Deloye, F., Lozzl, L., and Shone, C. C. (1994) SNARE motif and neurotoxins, Nature 372, 415-416.
27. Pellizzari, R., Mason, S., Shone, C., and Montecucco, C. (1997) The interaction of synaptic vesicle-associated membrane protein/synaptobrevin with botulinum neurotoxins D and F, FEBS Lett. 409, 339-342.
28. Shone, C. C., Quinn, C. P., Wait, R., Hallis, B., Fooks, S. G., and Hambleton, P. (1993) Proteolytic cleavage of synthetic fragments of vesicle-associated membrane protein, isoform-2 by botulinum type B neurotoxin, Eur. J. Biochem. 217, 965-971.
29. Shone, C. C., and Roberts, A. K. (1994) Peptide substrate specificity and properties of the zinc-endopeptidase activity of botulinum type B neurotoxin, Eur. J. Biochem. 225, 263-270.
30. Schmidt, J. J., and Bostian, K. A. (1995) Proteolysis of synthetic peptides by type A botulinum neurotoxin, J. Protein Chem. 14, 703-708.
31. Schmidt, J. J., and Bostian, K. A. (1997) Endoproteinase activity of type A botulinum neurotoxin: Substrate requirements and activation by serum albumin, J. Protein Chem. 16, 19-26.
32. Anne, C., Cornille, F., Lenoir, C., and Roques, B. P. (2001 ) High-throughput fluorigenic assay for determination of botulinum type B neurotoxin protease activity, Anal. Biochem. 291, 253-261.
33. Schmidt, J. J., Stafford, R. G., and Millard, C. B. (2001) High-throughput assays for botulinum neurotoxin proteolytic activity: Serotypes A, B, D, and F, Anal. Biochem. 296, 130-137.
34. Schmidt, J. J., and Stafford, R. G. (2003) Fluorigenic substrates for the protease activities of botulinum neurotoxins, serotypes A, B, and F, Appl. Environ. Microbiol. 69, 297-303.
35. 1′ binding subsite, FEBS Lett. 435, 61-64.
36. Schmidt, J. J., and Stafford, R. G. (2002) A high-affinity competitive inhibitor of type A botulinum neurotoxin A metalloprotease activity, FEBS Lett. 532, 423-426.
37. Burnett, J. C., Schmidt, J. J., Stafford, R. G., Panchal, R. G., Nguyen, T. L., Hermone, A. R., Vennerstrom, J. L., McGrath, C. F., Lane, D. J., Sausville, E. A., Zaharevitz, D. W., Gussio, R., and Bavari, S. (2003) Novel small molecule inhibitors of botulinum neurotoxin protease activity, Biochem. Biophys. Res. Commun. 310, 85-94.
38. Sukonpan, C., Oost, T., Goodnough, M., Tepp, W., Johnson, E. A., and Rich, D. H. (2004) Synthesis of substrates and inhibitors of botulinum neurotoxin type A metalloprotease, J. Pept. Res. 63. 181-193.
39. Adler, M., Nicholson, J. D., and Hackley, B. E. (1998) Efficacy of a novel metalloprotease inhibitor on botulinum neurotoxin B activity, FEBS Lett. 429, 234-238.
40. Garcia, G. E., Moorad, D. R., and Gordon, R. K. (1999) Buforin I, a natural peptide, inhibits botulinum neurotoxin B activity in vitro, J. Appl. Toxicol. 19, S19-S22.
41. Eswaramoorthy, S., Kumaran, D., and Swaminathan, S. (2002) A novel mechanism for Clostridium botulinum neurotoxin inhibition, Biochemistry 41, 9795-9802.
42. Blommaert, A., Turcaud, S., Anne, C., and Roques, B. P. (2004) Small tripeptide surrogates with low nanomolar affinity as potent inhibitors of the botulinum neurotoxin B metallo-proteolytic activity, Bioorg. Med. Chem. 12, 3055-3062.
43. Oost, T., Sukonpan, C., Brewer, M., Goodnough, M., Tepp, W., Johnson, E. A., and Rich, D. H. (2003) Design and synthesis of substrate-based inhibitors of botulinum neurotoxin type B metalloprotease, Biopolymers 71, 602-619.
44. Martin, L., Cornille, F., Coric, P., Roques, B. P., and Fournie-Zaluskie, M. C. (1998) β-Amino thiols inhibit the zinc metallopeptidase activity of tetanus toxin light chain, J. Med. Chem. 41, 3450-3460.
45. Martin, L., Cornille, F., Turcaud, S., Meudal, H., Roques, B. P., and Fournie-Zaluskie, M. C. (1999) Metallopeptidase inhibitors of tetanus toxin: A combinatorial approach, J. Med. Chem. 42, 515-525.
46. Segel, I. H. (1975) Enzyme kinetics, pp 109-111, Wiley, New York.
47. Henderson, P. J. (1972) A linear equation that describes the steadystate kinetics of enzymes and subcellular particles interacting with tightly bound inhibitors, Biochem. J. 127, 321-333.
48. Vadakkanchery, V. V., Yoshino, K., Jahnz, M., Dürries, C., Bade. S., Nauenberg, S., Nieman, H., and Binz, T. (1999) Proteolysis of SNAP-25 isoforms by botulinum neurotoxin types A, C, and E: Domains and amino acid residues controlling the formation of enzyme-substrate complexes and cleavage, J. Neurochem. 72, 327-337.
49. Bohacek, R., De Lombaert, S., McMartin, C., Priestle, J., and Grütter, M. (1996) Three-dimensional models of ACE and NEP inhibitors and their use in the design of potent dual ACE/NEP inhibitors, J. Am. Chem. Soc. 118, 8231-8249.
50. Natesh, R., Schwager, S. L., Sturrock, E. D., and Acharya, K. R. (2003) Crystal structure of the human angiotensin-converting enzyme-lisinopril complex, Nature 421, 551-554.
51. Auge, F., Hornebeck, W., and Laronze, J. Y. (2004) A novel strategy for designing specific gelatinase A inhibitors: Potential use to control tumor progression, Crit. Rev. Oncol. Hematol. 49, 277-282.
52. Betz, M., Huxley, P., Davies, S. J., Mushtaq, Y., Pieper, M., Tschesche, H., Bode, W., and Gomis-Rüth, F. X. (1997) 1.8-Å crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate primed-side inhibitor with a distinct selectivity profile, Eur. J. Biochem. 247, 356-363.
53. Rosenblum, G., Meroueh, S. O., Kleifeld, O., Brown, S., Singson, S. P., Fridman, R., Mobashery, S., and Sagit, I. (2003) Structural basis for potent slow binding inhibiton of human matrix metalloproteinase-2 (MMP-2), J. Biol. Chem. 278, 27009-27015.
54. van Alten, D. M., Chong, C. R., and Joshua-Tor, L. (2000) Crystal structure of carboxypeptidase A complexed with D-cysteine at 1.75 Å: Inhibitor-induced conformational changes, Biochemistry 39, 10082-10089.
55. Cornille, F., Goudreau, N., Ficheux, D., Nieman, H., and Roques, B. P. (1994) Solid-phase synthesis, conformational analysis and in vitro cleavage of synthetic human synaptobrevin II 1-93 by tetanus toxin L chain, Eur. J. Biochem. 222, 173-181.